Cantargia (CANTA) Stock Overview

A biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. More details

CANTA fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 98.5% below our estimate of its fair value

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 54.8% per year for the next 3 years

Volatile share price over the past 3 months compared to the Swedish market

Does not have a meaningful market cap (SEK448M)

Community Fair Values

Cantargia AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cantargia
Historical stock prices
Current Share Price	SEK 1.80
52 Week High	SEK 6.59
52 Week Low	SEK 1.74
Beta	1.59
1 Month Change	-3.63%
3 Month Change	-47.41%
1 Year Change	-39.46%
3 Year Change	-57.31%
5 Year Change	-91.80%
Change since IPO	-79.96%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	CANTA	SE Biotechs	SE Market
7D	-1.6%	1.6%	-0.9%
1Y	-39.5%	23.9%	13.2%

Return vs Industry: CANTA underperformed the Swedish Biotechs industry which returned 23.9% over the past year.

Return vs Market: CANTA underperformed the Swedish Market which returned 13.2% over the past year.

Price Volatility

Is CANTA's price volatile compared to industry and market?
CANTA volatility
CANTA Average Weekly Movement	9.0%
Biotechs Industry Average Movement	9.0%
Market Average Movement	5.7%
10% most volatile stocks in SE Market	11.4%
10% least volatile stocks in SE Market	3.2%

Stable Share Price: CANTA's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: CANTA's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

Founded	Employees	CEO	Website
2009	22	Hilde Steineger	cantargia.com

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform.

Cantargia AB (publ) Fundamentals Summary

How do Cantargia's earnings and revenue compare to its market cap?
CANTA fundamental statistics
Market cap	SEK 448.50m
Earnings (TTM)	SEK 160.93m
Revenue (TTM)	SEK 317.21m

2.8x

P/E Ratio

1.4x

P/S Ratio

Is CANTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CANTA income statement (TTM)
Revenue	SEK 317.21m
Cost of Revenue	SEK 0
Gross Profit	SEK 317.21m
Other Expenses	SEK 156.28m
Earnings	SEK 160.93m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Aug 19, 2026

Earnings per share (EPS)	0.65
Gross Margin	100.00%
Net Profit Margin	50.73%
Debt/Equity Ratio	0%

How did CANTA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/08/13 03:49
End of Day Share Price	2026/08/13 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cantargia AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Arvid Necander	Carnegie Investment Bank AB
Soo Romanoff	Edison Investment Research
Sara Nik	H.C. Wainwright & Co.